REVENUES

Product Revenues

The Company’s net revenues consisted of the following for the three and nine months ended September 30, 2017 and 2016:



	Three months ended September 30,				Nine months ended September 30,
	2017		2016		2017		2016
Products:
Acetadote	$	1,342,457	$	1,807,495	$	4,331,675	$	5,532,893
Omeclamox-Pak	190,835		752,808		1,213,635		2,154,596
Kristalose	2,749,966		3,671,397		8,037,994		10,915,276
Vaprisol	385,541		496,279		1,346,793		1,286,126
Caldolor	896,640		1,357,289		2,762,790		3,060,441
Ethyol	2,566,611		519,400		8,325,254		519,400
Totect	2,916,425		—		2,916,425		—
Other	148,486		187,085		566,277		475,388
Total net revenues	$	11,196,961	$	8,791,753	$	29,500,843	$	23,944,120

Cumberland supplies Perrigo Company ("Perrigo") with an Authorized Generic version of the Company's Acetadote product. The Company's revenue generated by sales of its Authorized Generic distributed by Perrigo is included in the Acetadote product revenue presented above. The Company's share of Authorized Generic revenue was $0.9 million and $1.2 million for third quarter of 2017 and 2016 and $3.0 million and $3.5 million on a year-to-date basis as of September 30, 2017 and 2016, respectively. Totect revenue includes $0.3 million in Cardioxane net revenue for the third quarter of 2017.

Other Revenues

The Company has entered into agreements, beginning in 2012, with international partners for commercialization of the Company's products. The international agreements provide that each of the partners are responsible for seeking regulatory approvals for the products, and following approvals, each partner will handle ongoing distribution and sales in the respective international territories. The Company maintains responsibility for the intellectual property and product formulations. Under the international agreements, the Company is entitled to receive non-refundable, up-front payments at the time the agreements are entered into and milestone payments upon the partners' achievement of defined regulatory approvals and sales milestones. The Company recognizes revenue for these substantive milestones using the milestone method. The Company is also entitled to receive royalties on future sales of the products under the agreements.